Aldeyra receives complete response letter from FDA for reproxalap NDA
Aldeyra (ALDX) announced receipt of a complete response letter from the FDA for the resubmission of the new drug application of reproxalap, an ...
ZenaTech’s 2024 Financial Results and CEO Letter to Shareholders Shows Revenue and Assets Increase
As of December 31, 2024, and consistent with its recent 6K filing, ZenaTech’s 2024 full-year revenue increased by 7% to $1.96 million as compared to $1.82 million for the full year of 2023 (all ...